🚀 VC round data is live in beta, check it out!
Corbus Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Corbus Pharmaceuticals and similar public comparables like Vaxcell-Bio, Sangamo Therapeutics, Prestige Biologics, Mersana Therapeutics and more.
Corbus Pharmaceuticals Overview
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Founded
2009
HQ
Employees
28
Website
Sectors
Financials (LTM)
EV
$45M
Corbus Pharmaceuticals Financials
Corbus Pharmaceuticals reported last 12-month revenue of $449K.
In the same LTM period, Corbus Pharmaceuticals generated $449K in gross profit and had net loss of ($81M).
Revenue (LTM)
Corbus Pharmaceuticals P&L
In the most recent fiscal year, Corbus Pharmaceuticals reported revenue of — and EBITDA of ($78M).
Corbus Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $449K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $449K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($78M) | XXX | XXX | XXX |
| EBIT Margin | (19413%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($81M) | XXX | ($79M) | XXX | XXX | XXX |
| Net Margin | (18011%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Corbus Pharmaceuticals Stock Performance
Corbus Pharmaceuticals has current market cap of $147M, and enterprise value of $45M.
Market Cap Evolution
Corbus Pharmaceuticals' stock price is $8.37.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45M | $147M | 0.0% | XXX | XXX | XXX | $-4.47 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCorbus Pharmaceuticals Valuation Multiples
Corbus Pharmaceuticals trades at 100.1x EV/Revenue multiple, and (0.6x) EV/EBITDA.
EV / Revenue (LTM)
Corbus Pharmaceuticals Financial Valuation Multiples
As of March 24, 2026, Corbus Pharmaceuticals has market cap of $147M and EV of $45M.
Equity research analysts estimate Corbus Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corbus Pharmaceuticals has a P/E ratio of (1.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $147M | XXX | $147M | XXX | XXX | XXX |
| EV (current) | $45M | XXX | $45M | XXX | XXX | XXX |
| EV/Revenue | 100.1x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/EBIT | (0.5x) | XXX | (0.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 100.1x | XXX | — | XXX | XXX | XXX |
| P/E | (1.8x) | XXX | (1.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Corbus Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Corbus Pharmaceuticals Margins & Growth Rates
Corbus Pharmaceuticals' revenue in the last 12 month grew by 577%.
Corbus Pharmaceuticals' revenue per employee in the last FY averaged $0.0M.
Corbus Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 577% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 107% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3366% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16054% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Corbus Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vaxcell-Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Sangamo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Prestige Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mersana Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| vTv Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corbus Pharmaceuticals M&A Activity
Corbus Pharmaceuticals acquired XXX companies to date.
Last acquisition by Corbus Pharmaceuticals was on XXXXXXXX, XXXXX. Corbus Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Corbus Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCorbus Pharmaceuticals Investment Activity
Corbus Pharmaceuticals invested in XXX companies to date.
Corbus Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Corbus Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Corbus Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Corbus Pharmaceuticals
| When was Corbus Pharmaceuticals founded? | Corbus Pharmaceuticals was founded in 2009. |
| Where is Corbus Pharmaceuticals headquartered? | Corbus Pharmaceuticals is headquartered in United States. |
| How many employees does Corbus Pharmaceuticals have? | As of today, Corbus Pharmaceuticals has over 28 employees. |
| Who is the CEO of Corbus Pharmaceuticals? | Corbus Pharmaceuticals' CEO is Yuval Cohen. |
| Is Corbus Pharmaceuticals publicly listed? | Yes, Corbus Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Corbus Pharmaceuticals? | Corbus Pharmaceuticals trades under CRBP ticker. |
| When did Corbus Pharmaceuticals go public? | Corbus Pharmaceuticals went public in 2014. |
| Who are competitors of Corbus Pharmaceuticals? | Corbus Pharmaceuticals main competitors are Vaxcell-Bio, Sangamo Therapeutics, Prestige Biologics, Mersana Therapeutics. |
| What is the current market cap of Corbus Pharmaceuticals? | Corbus Pharmaceuticals' current market cap is $147M. |
| What is the current revenue of Corbus Pharmaceuticals? | Corbus Pharmaceuticals' last 12 months revenue is $449K. |
| What is the current revenue growth of Corbus Pharmaceuticals? | Corbus Pharmaceuticals revenue growth (NTM/LTM) is 577%. |
| What is the current EV/Revenue multiple of Corbus Pharmaceuticals? | Current revenue multiple of Corbus Pharmaceuticals is 100.1x. |
| Is Corbus Pharmaceuticals profitable? | No, Corbus Pharmaceuticals is not profitable. |
| What is the current net income of Corbus Pharmaceuticals? | Corbus Pharmaceuticals' last 12 months net income is ($81M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.